Recent advances in psychiatric medicines: from rapid-acting antidepressants to precision psychiatry

Abstract

Psychiatric disorders represent a leading cause of global disease burden, with depression, schizophrenia, bipolar disorder, and anxiety disorders contributing substantially to disability-adjusted life years worldwide. Despite decades of pharmacological research, conventional psychiatric medicines, primarily monoaminergic antidepressants and dopamine receptor–based antipsychotics, remain limited by delayed onset of action, incomplete response rates, relapse, and significant adverse effects. Over the past decade, however, psychiatric drug development has entered a transformative phase marked by the emergence of rapid-acting antidepressants, neuroactive steroid modulators, novel receptor targets, psychedelic-assisted therapies, and precision-based approaches. This mini-review critically examines recent advances in psychiatric medicines, focusing on mechanistic innovations, clinical evidence, regulatory milestones, and translational challenges. Key developments include glutamatergic modulators such as ketamine and esketamine, GABAergic neuroactive steroids for postpartum depression, muscarinic and trace amine-associated receptor 1 (TAAR1)-based antipsychotics, the resurgence of psychedelic research, advances in long-acting injectable formulations, and the integration of pharmacogenomics and biomarker-guided therapy. Collectively, these innovations signal a paradigm shift toward faster, more targeted, and individualized psychiatric treatment strategies.